Liver transplantation in patients with history of extra-hepatic malignancies.

Frontiers in transplantation Pub Date : 2026-03-05 eCollection Date: 2026-01-01 DOI:10.3389/frtra.2026.1723729
Jerry Xiao, Ashton A Connor, Ahmed Elaileh, Khush Patel, Samar Semaan, Youssef Dib, Jason Todd, Linda W Moore, Sudha Kodali, David W Victor Iii, Maen Abdelrahim, Anaum Maqsood, Caroline J Simon, Yee Lee Cheah, Constance M Mobley, Ashish Saharia, A Osama Gaber, R Mark Ghobrial, Kirk Heyne
{"title":"Liver transplantation in patients with history of extra-hepatic malignancies.","authors":"Jerry Xiao, Ashton A Connor, Ahmed Elaileh, Khush Patel, Samar Semaan, Youssef Dib, Jason Todd, Linda W Moore, Sudha Kodali, David W Victor Iii, Maen Abdelrahim, Anaum Maqsood, Caroline J Simon, Yee Lee Cheah, Constance M Mobley, Ashish Saharia, A Osama Gaber, R Mark Ghobrial, Kirk Heyne","doi":"10.3389/frtra.2026.1723729","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Increasing use of solid organ transplantation [SOT] has coincided with increasing cancer survivorship. Consensus statements exist for SOT in patients with pre-transplant malignancy [PTM]. Yet, most outcomes have been reported in heart and kidney transplant. This paper addresses the shortage of information on liver transplant [LT] in patients with PTM.</p><p><strong>Methods: </strong>A retrospective case-control study was conducted of patients who underwent LT between 1/1/2008-5/31/2024 at an American transplant center. Patients were stratified according to history of extrahepatic PTM, time from PTM to LT, and post-LT PTM recurrence. Primary outcomes were overall survival [OS] and time to recurrence.</p><p><strong>Results: </strong>1,876 patients underwent LT. 143(7.62%) had an extrahepatic PTM pre-LT. PTM patients were older and had lower MELD at LT. There was no significant difference in post-LT survival (<i>p</i> = 0.293) between patients who did and did not have PTM. Of 121 patients with known time from PTM to LT, 19(15.7%) had an interval less than 2 years. When stratifying by 2-year interval from PTM to LT, there was no difference in survival (<i>p</i> = 0.34). Post-LT, 20 patients (14.0%) had recurrence of their PTM. The average time to recurrence was 595.5 days. When treated as a time-dependent co-variate, recurrence was a strong predictor of worse post-LT survival (HR 10.9, 95% CI 4.32-27.7, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>In our experience<b>,</b> a history of pre-LT PTM, including with an interval to LT of less than 2 years, was not associated with worse post-LT survival. Recurrence of PTM did portend worse prognosis.</p>","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":"5 ","pages":"1723729"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2026.1723729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Increasing use of solid organ transplantation [SOT] has coincided with increasing cancer survivorship. Consensus statements exist for SOT in patients with pre-transplant malignancy [PTM]. Yet, most outcomes have been reported in heart and kidney transplant. This paper addresses the shortage of information on liver transplant [LT] in patients with PTM.

Methods: A retrospective case-control study was conducted of patients who underwent LT between 1/1/2008-5/31/2024 at an American transplant center. Patients were stratified according to history of extrahepatic PTM, time from PTM to LT, and post-LT PTM recurrence. Primary outcomes were overall survival [OS] and time to recurrence.

Results: 1,876 patients underwent LT. 143(7.62%) had an extrahepatic PTM pre-LT. PTM patients were older and had lower MELD at LT. There was no significant difference in post-LT survival (p = 0.293) between patients who did and did not have PTM. Of 121 patients with known time from PTM to LT, 19(15.7%) had an interval less than 2 years. When stratifying by 2-year interval from PTM to LT, there was no difference in survival (p = 0.34). Post-LT, 20 patients (14.0%) had recurrence of their PTM. The average time to recurrence was 595.5 days. When treated as a time-dependent co-variate, recurrence was a strong predictor of worse post-LT survival (HR 10.9, 95% CI 4.32-27.7, p < 0.001).

Conclusion: In our experience, a history of pre-LT PTM, including with an interval to LT of less than 2 years, was not associated with worse post-LT survival. Recurrence of PTM did portend worse prognosis.

Abstract Image

肝外恶性肿瘤病史患者的肝移植。
实体器官移植(SOT)应用的增加与癌症生存率的增加相一致。对于移植前恶性肿瘤患者存在SOT的共识声明[PTM]。然而,报道的大多数结果是心脏和肾脏移植。本文解决了PTM患者肝移植[LT]信息不足的问题。方法:对2008年1月1日至2024年5月31日在美国某移植中心接受肝移植的患者进行回顾性病例对照研究。根据肝外PTM的病史、PTM到LT的时间以及LT后PTM的复发情况对患者进行分层。主要结局为总生存期(OS)和复发时间。结果:1876例患者接受了肝移植,143例(7.62%)在肝移植前有肝外PTM。PTM患者年龄较大,lt时MELD较低。有PTM和没有PTM的患者lt后生存率无显著差异(p = 0.293)。在121例已知从PTM到LT时间的患者中,19例(15.7%)的间隔时间小于2年。从PTM到LT以2年间隔进行分层时,生存率无差异(p = 0.34)。术后,20例患者(14.0%)出现PTM复发。平均复发时间为595.5 d。当作为时间相关的协变量处理时,复发是肝移植后生存差的一个强有力的预测因子(HR 10.9, 95% CI 4.32-27.7, p)。结论:根据我们的经验,肝移植前PTM病史,包括肝移植间隔少于2年,与肝移植后生存差无关。PTM的复发预示着较差的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书